Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)
fluticasone furoate/vilanterol
HZC102871
NCT01009463
Pulmonary Disease, Chronic Obstructive
Phase 3
 
September 2013

Powered by ideaPoint, Inc.